NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, these findings describe a novel and crucial role for FAM167A in the noncanonical NF-κB pathway with respect to the mechanism of BCR-ABL-independent TKI resistance, suggesting a promising target for overcoming TKI-resistant CML.